CTLA4 and neoplasm: The anti-angiogenic effect of propranolol as a single agent treatment was also observed when used in combination with anti-CTLA4 in both the MCA205 (Fig. 7C, D) and MC38 tumor model (Supplementary Fig. S5A, B).